The Early versus Late Intervention Trial with Estradiol (ELITE) is one of the most important modern menopause studies. Its findings helped support the idea that the timing of hormone therapy initiation may influence cardiovascular outcomes.
Researchers wanted to understand whether starting estrogen therapy closer to menopause produced different effects compared with starting treatment many years later. Women were divided into:
The researchers then evaluated markers related to cardiovascular health.
Following the WHI study, many questions remained about whether age and timing influenced outcomes. The ELITE trial directly investigated whether treatment timing might explain some of the differences seen between women.
One of the key concepts emerging from menopause research is that hormone therapy may not have identical effects when started at different stages of life.
The ELITE trial contributed important evidence supporting the idea that timing matters when evaluating cardiovascular outcomes.
This does not mean hormone therapy should be used by everyone, but it does highlight why treatment decisions should be individualised.
Modern menopause care increasingly considers timing, symptoms and risk factors together.
The ELITE trial helped shift menopause discussions away from simplistic "good" or "bad" interpretations of hormone therapy. Instead, it reinforced the importance of personalised assessment.
Questions such as:
have become central to modern menopause medicine.
The ELITE trial reminds us that menopause care is not simply about whether hormone therapy is used, but when, why and for whom.
Book Assessment Browse Research Library